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cense. httpAbstract Introduction: This study aimed to investigate local control and survival rates following
abdominoperineal resection (APR) compared with low anterior resection (LAR) in lower and mid-
dle rectal cancer.
Methods: In this retrospective study, 153 patients with newly histologically proven rectal adenocar-
cinoma located at low and middle third that were treated between 2004 and 2010 at a tertiary hos-
pital. The tumors were pathologically staged according to the 7th edition of the American Joint
Committee on Cancer (AJCC) staging system. Surgery was applied for 138 (90%) of the patients,
of which 96 (70%) underwent LAR and 42 were (30%) treated with APR. Total mesorectal excision
was performed for all patients. In addition, 125 patients (82%) received concurrent (neoadjuvant,
adjuvant or palliative) pelvic chemoradiation, and 134 patients (88%) received neoadjuvant, adju-
vant or concurrent chemotherapy. Patients’ follow-up ranged from 4 to 156 (median 37) months.
Results: Of 153 patients, 89 were men and 64 were women with a median age of 57 years. Oneolorectal Research Center,
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152 S. Omidvari et al.patient (0.7%) was stage 0, 15 (9.8%) stage I, 63 (41.2%) stage II, 51 (33.3%) stage III and 23
(15%) stage IV. There was a signiﬁcant difference between LAR and APR in terms of tumor dis-
tance from anal verge, disease stage and combined modality therapy used. However, there was no
signiﬁcant difference regarding 5-year local control, disease free and overall survival rates between
LAR and APR.
Conclusion: LAR can provide comparable local control, disease free and overall survival rates
compared with APR in eligible patients with lower and middle rectal cancer.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Colorectal cancer is the ﬁfth most frequently diagnosed can-
cer and the leading cause of cancer death in developing coun-
tries [1]. In Iran, colorectal cancer is the fourth most
commonly diagnosed cancer in males and the second in fe-
males [2]. In the west, approximately one-third of cases occur
in the rectum and two-thirds in the colon [3]. However, in
Iran, rectum accounts for 40% of all primary sites in colorec-
tal cancer [2,4]. Surgery is the standard approach of curative
treatment in rectal cancer. Small cancers with superﬁcial inva-
siveness may be successfully treated with limited surgery, such
as local excision. However, the majority of rectal cancers
present at more advanced stages that need more extensive
surgery, such as low anterior resection (LAR) or abdomino-
perineal resection (APR). A remarkable portion of rectal can-
cers present with locally advanced tumors adhering or
invading to neighboring structures such as the prostate, blad-
der sacral bone or pelvic sidewalls. Therefore, these tumors
may be unresectable or potentially resectable at diagnosis
and primary surgery is associated with signiﬁcant risk of loco-
regional recurrence [5]. Neoadjuvant chemoradiation im-
proves tumor resectability, locoregional control, and
colostomy free survival rates in locally advanced rectal can-
cer. Currently, neoadjuvant chemoradiation followed by total
mesorectal excision is considered as standard of care for pa-
tients with stage II or III rectal cancer. [6–8]. In addition,
the use of neoadjuvant chemoradiation and adjuvant chemo-
therapy in these patients increase overall survival rate [8,9].
There is a surgical therapeutic challenge in tumors located
in lower rectum. Sphincter saving with coloanal anastomosis
in LAR has become an established option for low rectal can-
cer; however, most patients with rectal cancer involving anal
canal are routinely treated with APR [5,10,11]. Radial margin
involvement is directly correlated with advanced disease stage
and larger tumor. Rectal cancers treated by APR tend to
present at lower rectal part and to have more locally ad-
vanced stage. [12]. Consequently these tumors show a higher
rate of radial margin involvement, local recurrence and a
poorer outcome compared to those treated with LAR
[11,13,14]. Some studies suggested that extended APR such
as cylindrical resection is associated with a lower rate of ra-
dial margin involvement and improved local control rate
compared to conventional APR [15,16]. In addition, there
are some concerns regarding the efﬁcacy and safety of laparo-
scopic total mesorectal excision (TME) in patients with lower
rectal cancer [17–19]. Therefore, there are many controversies
regarding the oncologic outcome of LAR compared to APR
in lower rectal cancers [11]. The present study aimed to inves-
tigate local control and survival rates following LAR com-
pared with APR in lower and middle rectal cancer.Methods and materials
Population study and patient evaluation
This retrospective study was carried out at radiation oncology
department of a tertiary academic hospital. We analyzed the
characteristics, prognostic factors and survival of all (n= 153)
patients with newly histologically proven rectal adenocarcinoma
who were treated and followed-up between January 2004 and
January 2010 at our department. Patients with other epithelial
pathologies such as squamous cell carcinoma, or non epithelial
tumors; as well as recurrent disease were excluded. In addition,
only rectal tumors located below 12 cm from the anal verge were
included and those with upper rectal or rectosigmoid location
were excluded. The tumors were pathologically staged according
to the 7th edition of the American Joint Committee on Cancer
(AJCC) staging system [20]. Clinical staging was performed using
imaging studies in patients who received neoadjuvant chemoradi-
ation. Preliminary evaluation included comprehensive history
and physical examination, colonoscopy, abdominal and pelvic
ultrasonography and computed tomography (CT) scans and/or
pelvic MRI and/or transrectal ultrasonography. In our center,
abdominal and pelvic ultrasound is routinely used as workup
in colorectal disease, mainly as a complementary imaging to
CT scan for showing and differentiating discrete liver lesions.
Surgical technique
Total mesorectal excision was performed using laparoscopic
(12%) or open (88%) approach. Surgical technique depended
on surgeons’ experience and hospital facilities. The decision
for performing sphincter-preserving surgery was based on the
proximity of the tumor to the anal sphincter, the status of pre-
operative sphincter function, clinical response to neoadjuvant
therapy, surgeon’s experience and patient’s preference. Tumors
with adequate distal margin were treated with sphincter-pre-
serving surgery through low anterior resection and stapled or
handsewn coloanal anastomosis. After removing the rectum,
colonic J-pouch and coloanal anastomosis procedures were
performed. A temporary diverting loop ileostomy or colos-
tomy was performed in all the patients for protecting the anas-
tomosis. However, patients with preoperative poor sphincter
function, inadequate distal margin, or involvement of external
anal sphincter were managed by abdominoperineal resection
and permanent colostomy.
Neoadjuvant and adjuvant therapies
Concurrent neoadjuvant chemoradiation consisted of conven-
tional external beam radiotherapy using megavoltage linear
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was delivered via a daily fraction of 1.8–2 Gy, with ﬁve frac-
tions per week. Concurrent chemotherapy consisted of oral
capecitabine 825 mg/m2 twice daily during the whole period
of pelvic radiotherapy with weekend breaks or intravenous bo-
lus 5-ﬂuorouracil 425 mg/m2/day and leucovorin 20 mg/m2/
day on days 1–5 of the ﬁrst and last week of radiation. Neoad-
juvant chemotherapy consisted of capecitabine 1000 mg/m2
twice daily for 14 days of every 3 week cycle plus oxaliplatin
130 mg/m2 intravenously on day 1 (CAPEOX regimen); or
oxaliplatin 85 mg/m2 day 1, plus two-hour infusional leucovo-
rin 200 mg/m2 days 1 and 2, followed by bolus 5-FU 400 mg/
m2 and then 5-FU 600 mg/m2 over 22-h infusion days 1 and 2,
every two weeks (FOLFOX regimen). Patients who received
neoadjuvant chemoradiation underwent standard curative sur-
gery with at least 4–6 weeks interval. Adjuvant chemotherapy
regimens consisted of capecitabine monotherapy, bolus 5-FU/
leucovorin, FOLFOX, CAPEOX or irinotecan-based combi-
nations. All patients but 19 received a median 6 (range 4–8) cy-
cles of chemotherapy. Targeted therapy by bevacizumab and/
or cetuximab was only used in metastatic cases.
Statistical analysis
Clinical and pathological variables were analyzed using the
SPSS for Windows version 17 statistical software (SPSS, Chi-
cago, IL). Categorical variables of patient demographics (such
as sex and performance status, categorized age), tumor charac-
teristics (such as location, differentiation, and stage) and treat-
ment modalities (such as type of surgery, treatment modality,
and type of chemotherapy) were compared by using chi-square
tests and for continuous variables such as patients’ age and
radiation dose Student t tests and Analysis of Variance (ANO-
VA) test were used. Local control rate was deﬁned as the pro-
portion of patients who were free of locoregional recurrent
disease at 5 years. Disease-free survival rate was deﬁned as
the percentage of patients who were free of rectal cancer at
5 years; an overall survival rate was deﬁned as the percentage
of patients who were alive at 5 years. The survival durations
were measured from the date of initial treatment till the events
of locoregional failure (locoregional control), any type of treat-
ment failure (disease free survival), death from any reason
(overall survival) or the last follow-up. The signiﬁcance of dif-
ferences in survival was evaluated using the log-rank test. Kap-
lan–Meier was used to estimate survival experience of the
different groups of the prognostic factors. Multiple-covariate
analysis was performed using the stepwise regression hazards
regression model. The hazard ratio (HR) for death, with the
95% conﬁdence interval (CI) was calculated for the variable
groups. The log-rank test was used to compare treatment re-
sults in each variable group. All P values were 2-tailed and P
values less than 0.05 were considered statistically signiﬁcant.
Results
Age and sex
Of 153 patients, 89 were men and 64 were women. The age at
presentation was in the range of 23–84 years with a mean of
57.15 years. The peak frequency was observed between the
sixth and seventh decade of life in both sex.Stage of disease
One patient (0.7%) had stage 0, 15 (9.8%) had stage I, 63
(41.2%) had stage II, whereas 51 (33.3%) had stage III and
23 (15%) had stage IV disease. (Table 1).
Surgical type distribution
Surgery was applied for 138 (90%) of the patients, of which 96
(70%) underwent low-anterior resection (LAR) and 42 (30%)
were treated with abdominoperineal resection (APR). (Table 2)
In addition, 125 patients (82%) received concurrent pelvic che-
moradiation and a mean total dose of 48.43 (range 20–50.4)
Gy was delivered. The distributions of treatment schedules
by disease stage; type of surgery by disease stage; and surgical
type by time of radiotherapy are shown in the Tables 1 and 2
respectively. In addition, the distribution of patients’ and tu-
mor characteristics by types of surgery are shown and analyzed
in the Table 3. Accordingly, the distribution of tumor stage
(P< 0.001), tumor distance from anal verge (P< 0.001), sur-
gical margin status (P< 0.001), treatment modality
(P= 0.005), the dose of radiotherapy (P< 0.001), and che-
motherapy regimen (P= 0.015), were statistically different
among surgical treatment groups. Advanced disease stages
were more frequent among APR (52.4%) and non surgical
(93.3%) groups compared to LAR ones (39.6%). Lower rectal
tumors were more frequent among APR (92.9%) compared to
LAR (28.1%) and non surgical (46.7%) ones. The rate of free
surgical margin was higher among LAR (77.1%) and APR
(83.3%) compared to non surgical (6.7%) ones. Mean dose
of radiotherapy used was higher among LAR (49.4 Gy) and
APR (48.9 Gy) compared to non surgical (41.4 Gy) cases. In
addition, the use of chemotherapy, particularly oxaliplatin-
based chemotherapy was more frequent in non surgical pa-
tients (60%) compared to LAR (46.9%) and APR (30.9%)
cases (Table 3). By excluding patients with non surgical treat-
ment and stage IV disease, there was a signiﬁcant difference in
terms of disease stage (P= 0.001), tumor distance from anal
verge (P= 0.001), and combined modality therapy used
(P= 0.005) between LAR and APR.
Resection margins
Mean tumor distance from the anal verge was 3.07 (range 0–8)
cm in APR cases and 8.13 (range 3–12) cm in LAR ones. Of
138 patients who underwent surgical resection, 110 patients
(80%) had free margin, 6 (4%) had involved and 13 (9%)
had close (1–9 mm) margin, whereas resection margin infor-
mation was not mentioned in 24 (17%) of patients. Six margin
involvements included 3 involved distal margins in LAR and 3
involved circumferential resected margins in APR. There was
no signiﬁcant difference in terms of surgical margin status be-
tween LAR and APR groups (chi-square test, P= 0.407).
Chemoradiation
In this study, 16 patients with stage 0–I were treated with sur-
gery alone. Of 114 cases with stage II and III, 83 patients
(73%) received adjuvant chemoradiation and 24 (21%) re-
ceived neoadjuvant chemoradiation (Table 1). In addition, of
23 patients with stage IV, 78% received palliative or curative
Table 1 Distribution of disease stage and treatment schedules in 153 patients with rectal cancer.
Treatment schedules Total Stage of disease
0–I II III IV
Surgery alone (%) 19 16 (84.2) 3 (15.8) 0 (.0) 0 (.0)
Combined therapy (%) 119 0 (.0) 59 (49.6) 49 (41.2) 11 (9.2)
Non surgical therapy (%) 15 0 (.0) 1 (6.7) 2 (13.3) 12 (80.0)
Total (%) 153 16 (10.5) 63 (41.2) 51 (33.3) 23 (15.0)
Table 2 Distribution of surgical type and time of radiother-
apy in 153 patients with rectal cancer.
Type of surgery Total Time of radiotherapy
Postoperative Preoperative No RT
LAR (%) 96 67 (69.8) 14 (14.6) 15 (15.6)
APR (%) 42 22 (52.4) 8 (19.0) 12 (28.6)
No surgery (%) 15 0 (0.0) 14 (93.3)a 1 (6.7)
Total (%) 153 89 (58.2) 36 (23.5) 28 (18.3)
LAR, low anterior resection; APR, abdominoperineal resection;
RT, radiotherapy.
a Preoperative or palliative intent.
Table 3 Distribution of the patients’ and the tumor characteristics
Variables No Surgery
LAR
Age (years)
Mean (±SD) 57.15 (13.95) 57.25 (14.
<55 (%) 71 49 (69.0)
P55 (%) 82 47 (57.3)
Sex (%)
Male 89 57.25 (14.
Female 64 49 (69.0)
Stage (%)
0–II 79 53 (59.5)
III–IV 74 43 (67.2)
Tumor grade (%)
Grade I 120 75 (62.5)
Grade II–III 33 21 (63.6)
Tumor distance from anal verge (%)
Mean (±SD) 6.56 8.13 (2.80
Lower third (0–6 cm) 73 27 (37.0)
Middle third (7–12 cm) 80 69 (86.3)
Surgical margin status (%)
Free 110 74 (67.3)
Involved or closed or NM 43 22 (51.2)
Treatment modality (%)
Surgery alone 19 8 (42.1)
Combined therapy 119 88 (73.9)
Dose of radiotherapy (%)
Mean (±SD) 48.43 49.37 (2.4
Chemotherapy regimen (%)
No chemotherapy 19 8 (42.1)
Oxaliplatin-based 67 45 (67.2)
Other regimens 67 43 (64.2)
LAR; low anterior resection, APR; abdominoperineal resection; SD
apy ± chemoradiation; NM, not mentioned.
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24 patients with stage II and III who received neoadjuvant che-
moradiation, 21 (87.5%) underwent LAR (n= 13) or APR
(n= 8). Of 3 remaining patients, 2 refused surgery (n= 2)
and the last patient was inoperable (Table 2).
Survival rates and prognostic factors
The 5-year disease free survival (DFS) and overall survival
(OS) were 53.4% and 69.4%, respectively (Figures 1 and 2).
Potential prognostic variables were analyzed to establish
their inﬂuence on the disease free and overall survival rates
of patients with rectal cancer. On univariate analysis using
log rank test of prognostic factors for DFS, age (log rank test,by surgery in 153 patients with rectal cancer.
P value
APR No surgery
19) 55.40 (13.01) 61.22 (14.90) 0.395
19 (26.8) 3 (4.2)
23 (28.1) 12 (14.6) 0.08
19) 25 (28.1) 11 (12.4)
17 (26.5) 4 (6.3) 0.408
20 (25.3) 1 (1.3)
22 (29.7) 14 (18.9) <0.001
34 (28.3) 11 (9.2)
8 (24.3) 4 (12.1) 0.821
) 3.07 (2.17) 6.26 (3.69) <0.001
39 (53.4) 7 (9.6)
3 (3.7) 8 (10.0) <0.001
35 (31.8) 1 (0.9)
7 (16.3) 14 (32.5) <0.001
11 (57.9) –
31 (26.1) – 0.005
4) 48.91 (3.42) 41.47 (10.46) <0.001
11 (57.9) 0 (0.0)
13 (19.4) 9 (13.4)
18 (26.9) 6 (9.0) 0.015
; standard deviation, combined therapy; surgery ± chemother-
Figure 1 Kaplan–Meier survival curves of 5-year disease-free
survival in 153 patients with rectal cancer.
Figure 2 Kaplan–Meier survival curves of 5-year overall sur-
vival in 153 patients with rectal cancer.
Comparison of abdominoperineal resection and low anterior resection 155P< 0.001), stage of disease (log rank test, P< 0.001), treat-
ment modality (log rank test, P< 0.001), surgical margin sta-
tus (log rank test, P= 0.001), and chemotherapy regimen (log
rank test, P= 0.018) were found to be prognostic factors.
However, there was no signiﬁcant difference in terms of DFS
rate between LAR and APR groups (54.4% versus 60.7%,
log rank test, P= 0.842). Sex, tumor differentiation and dose
of radiation were found not to be prognostic factors for DFS
(Table 4).
Regarding local control, age (log rank test, P= 0.005),
stage of disease (log rank test, P< 0.001), surgical margin sta-
tus (log rank test, P< 0.001) and treatment modality used
(log rank test, P< 0.001) were found to be prognostic factors
for local control. However, local control between LAR
(84.8%) and AP resection groups (81.0%) was not statistically
signiﬁcant (log rank test, P= 0.533). (Table 5) On multivari-
ate analysis, only stage of disease was independent prognostic
factor. Stage III (Hazard ratio (HR) = 0.01, 95% CI = 0.01–0.22, P< 0.001), and stage IV (HR= 0.01, 95% CI = 0.03–
0.41, P< 0.001) had a negative inﬂuence on local control.
(Table 6).
On univariate analysis of prognostic factors for OS, age
(log rank test, P< 0.001) (Figure 3), stage of disease (log rank
test, P< 0.001) (Figure 4), treatment modality (log rank test,
P< 0.001), chemotherapy regimen (log rank test, P= 0.048),
and dose of radiation (log rank test, P= 0.017) were found to
be prognostic factors. Sex, tumor differentiation, surgical mar-
gin status and were found not to be prognostic factors for OS
(Table 5). In addition, there was no signiﬁcant difference in
terms of overall survival rate between LAR and APR groups
(68.7% versus 84.0%, log rank test, P= 0.256) (Figure 5).
On multivariate analysis, only age and disease stage were
found to be independent prognostic factors. AgeP 55 years
[HR= 5.86, 95% CI = 2.49–13.79, P< 0.001], and stage IV
[HR= 36.90, 95% CI = 4.76–285.68, P< 0.001] had a nega-
tive inﬂuence on survival. (Table 7).
Pattern of recurrence
Sixty patients developed recurrent disease after treatment. Of
which 12 patients had locoregional recurrence at anastomotic
site wall, perineum, inguinal lymph nodes or within pelvic cav-
ity, 12 patients had isolated distant relapse, and 36 remaining
patients developed distant and locoregional recurrence. The
median time to recurrence was 9 months.Discussion
Low anterior resection and abdominoperineal excision are two
most commonly major surgical techniques used in lower and
middle rectal cancers. There are no signiﬁcant demographic
differences between LAR and APR in rectal cancer patients
[11]. In a meta-analysis, the mean age of 3363 patients with
rectal cancer was 60 years; and 65% of all patients were male
[8]. In the present study, the median age of all patients was
57 years and 58% of all patients were men. These results are
consistent with the literature [8]. In a systematic review, there
was no signiﬁcant difference between LAR and APR in terms
of patients’ age. In the current study, we did not ﬁnd signiﬁ-
cant difference regarding the patients’ age and sex between
LAR and APR.
It is evident that APR surgery is more commonly used in
low lying rectal tumors involving anal canal than LAR
[21,22]. In the present study, APR was associated with shorter
tumor distance from anal verge than LAR. There is debate
regarding an association between more locally advanced dis-
eases and APR surgery. Some reports indicate APR is more
like to be associated with locally advanced tumors than LAR
[23–25]; however, most studies found no signiﬁcant difference
between tumor stage and surgical type [11]. In our series, we
found tumors treated with APR were signiﬁcantly more locally
advanced than those treated by LAR. This ﬁnding is consistent
with some studies [23,24,26–30] and inconsistent with other re-
ports [11,24,27,31,32].
Several studies investigated the correlation of tumor differ-
entiation and surgical types or tumor location in rectal cancer
patients. Few studies reported a statistically signiﬁcant associ-
ation between poorly differentiated tumors and APR [24,27];
however, other studies did not ﬁnd such result [29,31–33]. In
Table 4 Prognostic factors for 5-year disease free- and overall survival in the 153 patients with rectal cancer.
Variables No 5-Year DFS (%) Log rank test
P value
5-Year OS (%) Log rank test
P value
Age (years) <0.001 <0.001
<55 71 70.3 87.3
P55 82 37.3 51.0
Sex 0.670 0.638
Male 89 52.1 70.0
Female 64 55.3 68.7
Stage <0.001 <0.001
0–I 16 86.5 93.3
II 63 64.6 78.3
III 51 48.7 70.3
IV 23 8.7 23.3
Tumor grade 0.868 0.517
Well diﬀerentiated 120 54.9 68.8
Moderately diﬀerentiated 28 47.7 75.4
Poorly diﬀerentiated 5 60.0 60.0
Tumor location 0.755 0.413
Lower rectal third 73 51.6 65.5
Middle rectal third 80 55.1 73.1
Surgical margin status
Free 110 60.7 0.001 75.0 0.052
Involved or closed 30 33.3 61.5
Not mentioned 13 46.2 50.5
Treatment modality <0.001 <0.001
Surgery alone 19 88.4 94.4
Combined therapy 119 50.9 69.0
Non Surgical treatment 15 20.0 33.0
Type of surgery 0.842 0.256
LAR 96 54.4 68.7
APR 42 60.7 84.0
Radiation dose
50–50.4 Gy 103 52.3 0.438 73.9 0.017
45–49 Gy 13 55.5 35.7
< 45 Gy 17 47.1 50.4
Chemotherapy regimen
No chemotherapy 19 88.4 0.018 94.4 0.048
Oxaliplatin-based 67 54.9 64.1
Other regimens 67 44.1 67.0
DFS, disease free survival; OS, overall survival; LAR, low anterior resection; APR, abdominoperineal resection; combined therapy, surgery plus
neoadjuvant and/or adjuvant therapies.
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ation and operation performed. Few studies investigated the
frequency of circumferential resected margin involvement in
rectal cancer patients. Most of these studies found a signiﬁ-
cantly higher rate of involved circumferential resection margin
following APR compared to LAR [27,28,30,32]. In the present
research, there was no signiﬁcant difference of involved cir-
cumferential resected margin between LAR and APR. Our re-
sults were consistent with the study of Hiranyakas et al. They
evaluated the incidence of a positive circumferential resected
margin in 154 patients who underwent curative APR
(n= 65) or LAR (n= 69). They concluded the rate of in-
volved circumferential resected margin was not signiﬁcantly
different between LAR and APR [34]. In agreement with this
study, we did not ﬁnd signiﬁcant difference between surgical
types and the rate of positive circumferential resected margin
in our patients. However, we found a different margin involve-
ment among LAR and APR. While all involved margins in
LAR were distal end and all involved margins in APR were
circumferential.There is controversy regarding the need of neoadjuvant or
adjuvant therapies in accordance with surgical type in rectal
cancer patients. Some reports concluded a more frequent use
of combined therapies among the patients undergoing APR
[26–28,35] or LAR [33]; while few reports found no signiﬁcant
difference in the use of combined therapies between APR and
LAR [29,36,37]. In the current study, the combined therapies
were used more frequently in LAR. This may be due to the
higher rate of stage IV and close margin in patients treated
with LAR.
Comparison of local recurrence rates is one of the most
important oncologic outcomes to assess the efﬁcacy of surgical
types used in rectal cancer patients. This endpoint was evalu-
ated by several studies. Most studies indicated greater rates
of local failure following APR [21,27,30,35]. Conversely, two
reports found higher rates of local recurrence among patients
treated by LAR [33,38]. On the other hand, several studies
did not ﬁnd signiﬁcant difference between local recurrence
rates and these two surgical types. Higher rates of involved cir-
cumferential resected margin and local failure in the literature
Table 5 Prognostic factors for 5-year local control rate in the 153 patients with rectal cancer.
Variables No 5-Year LC (%) Log rank test
P value
Age (years) 0.005
< 55 71 87.1
P55 82 68.8
Sex 0.571
Male 89 77.9
Female 64 79.5
Stage <0.001
0-I 16 92.3
II 63 89.6
III 51 81.0
IV 23 28.7
Tumor grade 0.963
Well diﬀerentiated 120 78.2
Moderately diﬀerentiated 28 79.6
Poorly diﬀerentiated 5 80.0
Tumor location 0.946
Lower rectal third 73 75.9
Middle rectal third 80 80.8
Surgical margin status <0.001
Free 110 86.0
Involved or closed 30 51.1
Not mentioned 13 80.8
Treatment modality <0.001
Surgery alone 19 93.3
Combined therapy 119 81.9
Non Surgical treatment 15 26.7
Type of surgery 0.533
LAR 96 84.8
APR 42 81.0
Radiation dose 0.391
50–50.4 Gy 103 78.2
45–49 Gy 13 92.3
< 45 Gy 17 76.5
Chemotherapy regimen 0.096
No chemotherapy 19 93.3
Oxaliplatin-based 67 77.4
Other regimens 67 76.2
LC, local control; LAR, low anterior resection; APR, abdominoperineal resection.
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tional APR. Some researchers concluded that extended APR
such as cylindrical resection is associated with a lower rate
of circumferential margin involvement and an improved local
control rate compared to conventional APR [15,16]. In this
study, we did not ﬁnd any statistically signiﬁcant different
local control rate between LAR and APR in our patients.Table 6 Multivariate stepwise regression hazards model
analysis of prognostic factors for local control in 153 patients
with rectal cancer.
Variables No Df P value Hazard ratio 95% CI
Stage 3
0–I 16
II 63 0.210 0.17 0.01–2.64
III 51 1 <0.001 0.01 0.01–0.22
IV 23 1 <0.001 0.01 0.03–0.41
CI, conﬁdence interval; Df, degrees of freedom.
Figure 3 Kaplan–Meier survival analysis of overall survival
categorized according to the patients’ age in 153 patients with
rectal cancer.
Figure 4 Kaplan–Meier survival analysis of overall survival
categorized according to the stage of disease in 153 patients with
rectal cancer.
Figure 5 Kaplan–Meier survival analysis of overall survival
categorized according to the type of surgery in 153 patients with
rectal cancer.
Table 7 Multivariate stepwise regression hazards model
analysis of prognostic factors for overall survival in 153
patients with rectal cancer.
Variables No Df P value Hazard ratio 95% CI
Age (years) 1 <0.001
<55 71
P55 82 1 <0.001 5.86 2.49–13.79
Stage <0.001
0–I 16 3 0.243 3.43
II 63 1 0.217 3.62 0.43–27.19
III 51 1 0.001 36.90 0.46–27.95
IV 23 1 0.243 3.43 4.76–285.68
CI, conﬁdence interval; Df, degrees of freedom.
158 S. Omidvari et al.Overall, we found a high overall recurrence rate in our pa-
tients. It is partly due to higher rate of cases with stage II
and III; as well as lower tendency to use neoadjuvant chemo-
radiation among general surgeons. While three-fourth cases
were stage II and III, only less than one-fourth received neoad-
juvant chemoradiation.
Some arguments are present regarding the impact of surgi-
cal types on disease free and overall survival rates. While some
reports did not ﬁnd any signiﬁcant different disease free sur-
vival among LAR and APR [29,35,39]; others found a better
disease-free survival for patients treated with LAR [21,24,30].
Likewise there is controversy regarding the prognostic effect
of surgical types on overall survival rates in rectal cancer pa-
tients. While most reports indicated improved overall survival
rates for LAR, few studies did not ﬁnd a signiﬁcant difference
between LAR and APR. In our report, there was no signiﬁcant
difference in terms of disease free survival and overall survival
between LAR and APR.
Low rectal cancers with anal canal involvement are usually
treated with APR; however, LAR may be considered as an
acceptable alternative, particularly in patients with excellent
response to neoadjuvant chemoradiation and with adequate
tumor margin from the anal canal. There is a remarkable risk
for local failure in these patients, particularly in those with un-
safe surgical margins. Therefore, close follow-up is mandatory
for patients treated with very LAR and salvage APR may be
reserved for local recurrent disease [10,33,40].
Conclusion
Low anterior resection and APR are two major surgical tech-
niques used in lower and middle rectal cancers. Low anterior
resection can provide comparable local control, disease free
and overall survival rates compared with APR in eligible pa-
tients with lower and middle rectal cancer.
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